FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Guide on Bispecific Antibody Development Programs

Federal Register notice: FDA makes available a draft guidance entitled Bispecific Antibody Development Programs.

Human Drugs

Teva Gains Approval for First Generic Narcan

FDA approves a Teva Pharmaceuticals ANDA for the first generic naloxone hydrochloride nasal spray (Adapt Pharmas Narcan), indicated for stopping or re...

Human Drugs

Safety Concerns with Pfizer/Lilly Trial of Tanezumab

Pfizer and Eli Lilly report safety concerns with a Phase 3 study comparing tanezumab 2.5 mg and 5 mg with nonsteroidal anti-inflammatory drugs in pati...

Human Drugs

MediciNova ALS Pivotal Trial Gets FDA Backing

FDA gives approval for MediciNova to proceed with a Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis patients.

Human Drugs

Akorn ANDA Approved for Generic Lotemax

FDA approves an Akorn ANDA for a generic copy of Bausch & Lombs Lotemax (loteprednol etabonate) ophthalmic suspension, 0.5%.

Medical Devices

FDA Clears Expanded Use for Medicreas Surgical Software

FDA clears a Medicrea Group 510(k) for expanded use of its proprietary surgical planning software, UNiD Hub.

Federal Register

Comments Extended for Sunscreen Proposed Rule

Federal Register notice: FDA extends the comment period for a 2/26 proposed rule on the regulation of over-the-counter sunscreen monograph products.

Federal Register

Proposed Rule on Sunscreens Corrected

Federal Register notice: FDA corrects a 2/26 proposed rule on the regulation of over-the-counter sunscreen monograph products.

Federal Register

Info Collection Extension for Animal ANDAs

Federal Register notice: FDA seeks comments on an information collection extension for Abbreviated New Animal Drug Applications Sections 512(b)(2) an...

Federal Register

Trisenox Not Withdrawn Over Safety/Efficacy: FDA

Federal Register notice: FDA determines that Cephalons Trisenox (arsenic trioxide) injection, 1mg/mL, was not withdrawn for safety or effectiveness re...